Tencent Technology (Shenzhen) Co. Ltd. has synthesized lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of cancer.
Researchers from Case Western Reserve University have filed for patent protection for a system and method for treating obesity or other gastric and/or metabolic disorders via closed-loop vagus nerve stimulation.
Ventus Therapeutics US Inc. has divulged pyrido-[3,4-d]pyridazine amine derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic, autoimmune disease, liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.
Alexion Pharmaceuticals Inc. has identified complement C1s subcomponent inhibitors reported to be useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic lateral sclerosis, Guillain Barré syndrome, Huntington’s disease, rheumatoid arthritis, traumatic brain injury, and autoimmune hemolytic anemia, among others.
The University of Minnesota has disclosed monocarboxylate transporter (MCT1) inhibitors reported to be useful for the treatment of cancer, graft-vs.-host disease, nonalcoholic steatohepatitis, obesity and diabetes.
In a new report from the U.S. International Trade Commission (USITC), concerns about global inequities accessing diagnostics and medicines for COVID-19 reveal that there are varied and divergent opinions on whether the intellectual property (IP) protections that support the development of new medicines may also act as a barrier to access, particularly in developing countries. In December 2022, U.S. Trade Representative Katherine Tai asked the USITC to respond and identify significant data and information gaps.
RSS
